133 related articles for article (PubMed ID: 11966681)
1. CYP2C9 polymorphisms and CYP2C9*2 genotyping primers.
Goldstein JA
Br J Clin Pharmacol; 2002 Apr; 53(4):409-10. PubMed ID: 11966681
[No Abstract] [Full Text] [Related]
2. CYP2C9 polymorphism and warfarin dose requirements.
Daly AK; Day CP; Aithal GP
Br J Clin Pharmacol; 2002 Apr; 53(4):408-9. PubMed ID: 11966680
[No Abstract] [Full Text] [Related]
3. Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy.
Furuya H; Fernandez-Salguero P; Gregory W; Taber H; Steward A; Gonzalez FJ; Idle JR
Pharmacogenetics; 1995 Dec; 5(6):389-92. PubMed ID: 8747411
[No Abstract] [Full Text] [Related]
4. Warfarin dose requirement and CYP2C9 polymorphisms.
Halkin H; Lubetsky A
Lancet; 1999 Jun; 353(9168):1972-3. PubMed ID: 10371596
[No Abstract] [Full Text] [Related]
5. CYP2C9 polymorphism: impact on tolbutamide pharmacokinetics and response.
Miners J
Pharmacogenetics; 2002 Mar; 12(2):91-2. PubMed ID: 11875362
[No Abstract] [Full Text] [Related]
6. Polymorphism of the cytochrome P450 (CYP) 2C9 gene in Japanese epileptic patients: genetic analysis of the CYP2C9 locus.
Imai J; Ieiri I; Mamiya K; Miyahara S; Furuumi H; Nanba E; Yamane M; Fukumaki Y; Ninomiya H; Tashiro N; Otsubo K; Higuchi S
Pharmacogenetics; 2000 Feb; 10(1):85-9. PubMed ID: 10739176
[No Abstract] [Full Text] [Related]
7. Identification of major CYP2C9 and CYP2C19 polymorphisms by fluorescence resonance energy transfer analysis.
Borlak J; Thum T
Clin Chem; 2002 Sep; 48(9):1592-4. PubMed ID: 12194942
[No Abstract] [Full Text] [Related]
8. Genetic analysis of CYP2C9 polymorphism in a Japanese population.
Nasu K; Kubota T; Ishizaki T
Pharmacogenetics; 1997 Oct; 7(5):405-9. PubMed ID: 9352578
[No Abstract] [Full Text] [Related]
9. Effects of CYP2C19 and CYP2C9 genetic polymorphisms on the disposition of and blood glucose lowering response to tolbutamide in humans.
Shon JH; Yoon YR; Kim KA; Lim YC; Lee KJ; Park JY; Cha IJ; Flockhart DA; Shin JG
Pharmacogenetics; 2002 Mar; 12(2):111-9. PubMed ID: 11875365
[TBL] [Abstract][Full Text] [Related]
10. Allelic and functional variability of cytochrome P4502C9.
Bhasker CR; Miners JO; Coulter S; Birkett DJ
Pharmacogenetics; 1997 Feb; 7(1):51-8. PubMed ID: 9110362
[TBL] [Abstract][Full Text] [Related]
11. Association of CYP2C9 genotypes leading to high enzyme activity and colorectal cancer risk.
Yasar U; Eliasson E; Dahl ML
Carcinogenesis; 2002 Apr; 23(4):665; author reply 667-8. PubMed ID: 11960920
[No Abstract] [Full Text] [Related]
12. Relationship of polymorphism in CYP2C9 to genetic susceptibility to diclofenac-induced hepatitis.
Aithal GP; Day CP; Leathart JB; Daly AK
Pharmacogenetics; 2000 Aug; 10(6):511-8. PubMed ID: 10975605
[TBL] [Abstract][Full Text] [Related]
13. The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement.
van der Weide J; Steijns LS; van Weelden MJ; de Haan K
Pharmacogenetics; 2001 Jun; 11(4):287-91. PubMed ID: 11434505
[TBL] [Abstract][Full Text] [Related]
14. CYP2C9*3 allelic variant and bleeding complications.
Ogg MS; Brennan P; Meade T; Humphries SE
Lancet; 1999 Sep; 354(9184):1124. PubMed ID: 10509530
[No Abstract] [Full Text] [Related]
15. Warfarin therapy in a patient homozygous for the CYP2C9 3 allele.
Ablin J; Cabili S; Lagziel A; Peretz H
Isr Med Assoc J; 2002 Feb; 4(2):139-41. PubMed ID: 11875991
[No Abstract] [Full Text] [Related]
16. The possession of the CYP2C9*3 allele is associated with low dose requirement of acenocoumarol.
Thijssen HH; Verkooijen IW; Frank HL
Pharmacogenetics; 2000 Nov; 10(8):757-60. PubMed ID: 11186138
[No Abstract] [Full Text] [Related]
17. Lung cancer risk in relation to the CYP2C9 genetic polymorphism among Caucasians in Los Angeles County.
London SJ; Sullivan-Klose T; Daly AK; Idle JR
Pharmacogenetics; 1997 Oct; 7(5):401-4. PubMed ID: 9352577
[No Abstract] [Full Text] [Related]
18. Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin.
Kidd RS; Curry TB; Gallagher S; Edeki T; Blaisdell J; Goldstein JA
Pharmacogenetics; 2001 Dec; 11(9):803-8. PubMed ID: 11740344
[TBL] [Abstract][Full Text] [Related]
19. Mutations of the CYP2C9 gene and the response to warfarin.
Yasar U; Oscarson M; Eliasson E; Sjöqvist F
Surgery; 2001 Mar; 129(3):384. PubMed ID: 11231472
[No Abstract] [Full Text] [Related]
20. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data.
Lee CR; Goldstein JA; Pieper JA
Pharmacogenetics; 2002 Apr; 12(3):251-63. PubMed ID: 11927841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
